Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT04888247

HighFLO Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve

Led by HighLife SAS · Updated on 2024-10-03

30

Participants Needed

14

Research Sites

500 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Feasibility, safety and performance of the HighLife CLARITY TSMV and its delivery system

CONDITIONS

Official Title

HighFLO Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Moderate-severe or severe mitral regurgitation (3+ or greater)
  • New York Heart Association (NYHA) Functional Class II, III, or ambulatory IV
  • Under guideline-directed medical therapy for at least one month as confirmed by the Heart Team
  • Assessed as high risk for open-heart surgery by the multidisciplinary Heart Team
  • Meets anatomical criteria for HighLife valve
  • Willing to participate and provides signed informed consent
  • High risk for left ventricular outflow tract obstruction (LVOTO)
Not Eligible

You will not qualify if you...

  • Stroke or transient ischemic attack (TIA) within 30 days
  • Severe symptomatic carotid stenosis (greater than 70% by imaging)
  • Active infections requiring antibiotics
  • Active ulcer or gastrointestinal bleeding within the past 3 months
  • History of bleeding disorders, coagulopathy, or refusal of blood transfusion
  • Inability to undergo transesophageal echocardiography (TEE)
  • Pregnant, lactating, or planning pregnancy within 12 months
  • Unable to comply with follow-up schedule and assessments
  • Participation in another clinical trial at enrollment
  • Known allergies to device components or contrast medium
  • Cannot tolerate anticoagulation or antiplatelet therapy
  • Life expectancy less than 12 months due to non-cardiac conditions
  • Permanent pacemaker or similar implanted cardiac device within the last 3 months

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 14 locations

1

Wesley Hospital

Auchenflower, Australia

Actively Recruiting

2

Mount Hospital

Perth, Australia

Actively Recruiting

3

Macquarie University Hospital

Sydney, Australia

Terminated

4

AZ St. Jan - Brugge

Bruges, Belgium

Actively Recruiting

5

UZ Leuven

Leuven, Belgium

Actively Recruiting

6

CHU Lille

Lille, France, 59000

Actively Recruiting

7

Centre Hospitalo - Univ de Nantes

Nantes, France, 44000

Actively Recruiting

8

CHU de Rennes

Rennes, France

Actively Recruiting

9

Cliniue Pasteur

Toulouse, France, 31076

Actively Recruiting

10

Deutsches Herzzentrum Munchen

Munich, Germany

Actively Recruiting

11

University Hospital Ulm

Ulm, Germany

Actively Recruiting

12

Medical University of Silesia

Katowice, Poland

Actively Recruiting

13

Medical University of Warsaw

Warsaw, Poland

Actively Recruiting

14

Brighton and Sussex University Hospital

Brighton, United Kingdom

Actively Recruiting

Loading map...

Research Team

L

Luc Verhees

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here